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BACKGROUND AND PURPOSE 
To address the questions of whether Δ9-tetrahydrocannabivarin (THCV) can (a) enhance 
activation of 5-HT1A receptors in vitro and (b) induce any apparent 5-HT1A receptor-mediated 
anti-psychotic effects in vivo. 
EXPERIMENTAL APPROACH 
In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat 
brainstem or human 5-HT1A CHO cells, using [
35
S]GTPγS and 8-[3H]-OH-DPAT binding assays. 
In vivo studies investigated whether THCV induces signs of 5-HT1A receptor-mediated anti-
psychotic effects in rats. 
KEY RESULTS 
We found that THCV (a) potently, albeit partially, displaced 8-[
3
H]-OH-DPAT from specific 
binding sites in rat brainstem membranes, (b) at 100 nM, significantly enhanced 8-OH-DPAT-
induced activation of receptors in these membranes, (c) produced concentration-related increases 
in 8-[
3
H]-OH-DPAT binding to specific sites in membranes of human 5-HT1A receptor-
transfected CHO cells, and (d) at 100 nM, significantly enhanced 8-OH-DPAT-induced 
activation of these human 5-HT1A receptors. In phencyclidine-treated rats, THCV, like clozapine, 
(a) reduced stereotyped behavior, (b) decreased time spent immobile in the forced swim test, and 
(c) normalized hyperlocomotor activity, social behaviour and cognitive performance. Some of 
these effects were counteracted by the 5-HT1A receptor antagonist, WAY100635, or could be 
produced by the CB1 antagonist, AM251.  
CONCLUSIONS AND IMPLICATIONS 
Our findings suggest that THCV can enhance 5-HT1A receptor activation, and that some of its 
apparent anti-psychotic effects may depend on this enhancement. We conclude that THCV has 
therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of 
schizophrenia.  
Abbreviations 
5-HT, 5-hydroxytryptamine; 8-OH-DPAT, 8-hydroxy-2-(di-n-propylamino)tetralin; AM251, 
N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide; CBD, cannabidiol; CBDA, cannabidiolic acid; CHO, Chinese hamster ovary; 
CLZ, clozapine; FST, forced swim test; NMDA, N-methyl-D-aspartate; NOR, novel object A
cc
ep
te
d 
A
rti
cl
e
-3- 
 
This article is protected by copyright. All rights reserved. 
recognition test; PCP, phencyclidine; THC, Δ9-tetrahydrocannabinol; THCV, Δ9-
tetrahydrocannabivarin  
Introduction  
In 2005, Russo et al. (2005) showed that one of the main components of Cannabis 
sativa, cannabidiol (CBD), in the micromolar range, binds to and functionally activates 
serotoninergic 5-HT1A receptors. More recently we have reported that, at concentrations in 
the nanomolar range, CBD as well as its immediate precursor cannabidiolic acid (CBDA) can 
enhance the ability of the selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT), to stimulate [
35S]GTPγS binding to rat brainstem 
membranes (Rock et al., 2012; Bolognini et al., 2013). Cannabigerol, another 
phytocannabinoid, has been reported by our group to behave as a potent apparent competitive 
antagonist of the 5-HT1A receptor (Cascio et al., 2010; Rock et al., 2011).  
The research described in this paper focused on the phytocannabinoid, Δ9-
tetrahydrocannabivarin (THCV) (Figure 1), a propyl-analogue of Δ9-tetrahydrocannabinol 
(THC), and on the 5-HT1A receptor. So far, it has been shown that this constituent of 
Cannabis can behave in both in vitro and in vivo experiments as a CB1 receptor antagonist 
(Thomas et al., 2005; Pertwee et al., 2007; Dennis et al., 2008; Ma et al., 2008), and a CB2 
receptor partial agonist (Bolognini et al., 2010). In addition, THCV has been reported to 
activate or block certain transient receptor potential (TRP) cation channels and to target 
GPR55 receptors (Anavi-Goffer et al., 2012; De Petrocellis et al., 2011; 2012). However, the 
ability of THCV to interact with 5-HT1A receptors has not yet been investigated.  
Here, for the first time, we present evidence that THCV (a) shares the ability of CBD 
to enhance 8-OH-DPAT-induced activation of 5-HT1A receptors in vitro in pharmacological 
assays performed with membranes obtained from rat brainstem or from CHO cells stably 
transfected with the human 5-HT1A and (b) produces, in rat models of schizophrenia-like 
symptoms, apparent anti-psychotic effects that are, at least in part, 5-HT1A receptor-mediated. 
Methods 
 
Receptor nomenclature 
The nomenclature of all the receptors mentioned in this paper conforms to BJP's Concise 
Guide to Pharmacology, Alexander et al., 2013. 
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Animals  
For in vitro experiments, brainstem tissues were obtained from 6 adult male Sprague Dawley 
rats maintained on a 12/12 h light/dark cycle with free access to food and water. These 
animals were purchased from Harlan UK Ltd (Blackthorn, UK). Before the removal of the 
brainstem, rats were killed by exposure to CO2 followed by cervical dislocation. All animal 
care and experimental procedures complied with the UK Animals (Scientific Procedures) Act, 
1986 and associated guidelines for the use of experimental animals. For in vivo experiments, 
male Sprague-Dawley rats (280-300g at the time of arrival) were purchased from Charles 
River (Calco, Italy) and randomly housed in groups of 4, on a 12/12 h light-dark cycle (lights 
on 08:00h) and in a temperature (24 ± 2°C) and humidity controlled environment (50 ± 10%), 
with a plastic tube for environmental enrichment. All animals had free access to food and 
water. We used a total of 204 rats that were randomly allocated to the experimental groups as 
follows: 18 control and 84 treated animals (6 rats for each experimental group) were tested 
for acute PCP experiments and 18 control and 84 treated animals (6 rats for each 
experimental group) were submitted to sub-chronic PCP experiments. All in vivo experiments 
were carried out during the light phase and performed in accordance with the guidelines 
released by the Italian Ministry of Health (D.L.116/92) and (D.L.111/94-B), and the 
European Community directives regulating animal research (86/609/EEC). All efforts were 
made to minimize the number of animals used and their suffering.  
Drugs and materials 
THCV, extracted from Cannabis sativa, was provided by GW Pharmaceuticals (Salisbury, 
UK). 8-OH-DPAT was supplied by Tocris (Bristol, UK). [
35S]GTPγS (1250 Ci mmol-1) and 
8-[
3
H]-OH-DPAT (135.2 Ci mmol
-1
) were purchased from PerkinElmer Life Sciences, Inc. 
(Boston, MA, USA), GTPγS and adenosine deaminase from Roche Diagnostic (Indianapolis, 
IN, USA), and GDP, DMSO and phencyclidine hydrochloride (PCP) from Sigma-Aldrich 
UK. Clozapine (CLZ), WAY100635 and AM251 were obtained from Tocris Bioscience 
(Italy). 
In vitro procedures 
CHO cells 
Chinese hamster ovary cells stably transfected with cDNA encoding human serotoninergic 5-
HT1A receptors (a generous gift from Dr Keith Parker) were maintained at 37°C and 5% CO2 
in Dulbecco’s modified Eagle’s medium nutrient mixture F-12 HAM supplemented with 2 A
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mM L-glutamine, 10% foetal bovine serum, 0.6% penicillin streptomycin and G418 (600 
mg·mL-1).  
Radioligand displacement assay 
Membranes from Sprague Dawley rat brainstem were prepared as described by Bolognini et 
al. (2013). Each assay was carried out with 0.7 nM [
3
H]-8-OH-DPAT, rat brainstem 
membranes (50 µg per well) or human 5-HT1A CHO cell membranes (50 µg per well) using 
Tris-binding buffer (50 mM Tris-HCl, 50 mM Tris-base, 0.1% BSA, pH 7.4), total assay 
volume 500 µl. All assays were performed at 37ºC for 60 min before termination by the 
addition of ice-cold Tris-binding buffer and vacuum filtration described previously by Ross et 
al. (1999b). Specific binding was defined by the presence and absence of 1 µM unlabeled 8-
OH-DPAT.  
[
35S]GTPγS binding assay 
Each assay was carried out with rat brainstem membranes (10 µg protein per well) or human 
5-HT1A CHO cell membranes (50 µg protein per well), GTPγS-binding buffer (50 mM Tris-
HCl; 50 mM Tris-Base; 5 mM MgCl2; 1 mM EDTA; 100 mM NaCl; 1mM dithiothreitol; and 
0.1% BSA), 0.1 nM [
35S]GTPγS and 30 µM GDP, in a final volume of 500 µl (Cascio et al., 
2010). Membranes from rat brainstem were pre-incubated for 30 min at 30ºC with 0.5 U ml
-1
 
adenosine deaminase (200 U ml
-1
) to remove any endogenous adenosine. Non-specific 
binding was measured in the presence of 30 µM GTPγS. Assays were performed at 30ºC for 
60 min (Cascio et al., 2010). 
 Dissociation Kinetics 
Dissociation kinetic assays were performed with the 5-HT1A receptor agonist 8-[
3
H]-OH-
DPAT (0.7 nM), human 5HT1A CHO cells (50 µg protein per well) and Tris-binding buffer, 
total assay volume 500 µl (Price et al., 2005). 8-[
3
H]-OH-DPAT was incubated with human 
5HT1A CHO cells for 60 min at 25ºC. Dissociation was initiated by the addition of 1 μM 
unlabeled ligand in the presence or absence of test compounds. Dissociation times of 0.5 to 
120 min at 25°C were used. Non specific binding was determined in the presence of a 1 μM 
concentration of the unlabeled ligand. Binding was terminated by addition of ice-cold wash 
buffer (50 mM Tris-HCl, 50 mM Tris-base, and 0.1% BSA) followed by vacuum filtration. 
In Vitro Data Analysis 
Values have been expressed as means and variability as SEM or as 95% confidence limits. 
Values for IC50, EC50, maximal effect (Emax) and SEM or 95% confidence limits of these 
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values have been calculated by nonlinear regression analysis using the equation for a sigmoid 
concentration-response curve (GraphPad Prism). The dissociation rate constant for 8-[
3
H]-
OH-DPAT was calculated using a one phase exponential decay equation (GraphPad Prism). P 
values <0.05 were considered significant. 
In vivo procedures 
Drug administration 
PCP was dissolved in saline and administered at a dose of 5 mg kg
-1
 i.p. (volume of injection 
1 ml kg
-1
). THCV was dissolved in ethanol, cremophor and saline (1:1:18) and administered 
at a dose of 2 mg kg
-1
 i.p. (volume of injection 5 ml kg
-1
), 30 min before the test. CLZ was 
dissolved in 0.2% acetic acid and saline and pH was adjusted to 6.5 using 10M NaOH. It was 
administered at a dose 2.5 mg kg
-1
 i.p. (volume of injection 5 ml kg
-1
), 30 min prior to testing. 
WAY100635 was dissolved in saline and administered at a dose of 1 mg kg
-1
 i.p. (volume of 
injection 1 ml kg
-1
), 45 min before the test sessions. AM251 was dissolved in DMSO, Tween-
80 and saline (1:1:8) and administered at a dose of 0.5 mg kg
-1
 i.p. (volume of injection 5 ml 
kg
-1
), 45 min before testing. 
Acute PCP administration 
Acute inhibition of the NMDA receptor induces positive-like symptoms of schizophrenia in 
rodents, such as hyperlocomotion and stereotypies, and this is a model often used to predict 
the effect of substances with potential antipsychotic properties (Bubenikova-Valesova et al., 
2008a; Large, 2007).  
At post-natal day 75, the effects of drug treatments on the stereotyped behaviour and 
increases in locomotor activity induced by acute PCP administration (5 mg kg
-1
 i.p.) were 
assessed according to the treatment schedule shown in ‘Results’.  
 
Sub-chronic PCP schedule 
A sub-chronic treatment regime with PCP followed by a washout period, with animals tested 
in the drug-free state, gives lasting cognitive deficits and negative-like signs with reasonable 
similarity to the neuropathological and behavioural disturbances of the disorder and is 
currently considered a useful model for testing the efficacy of novel antipsychotics against 
affective components and cognitive impairments of psychotic disorders (Neill et al., 2010, 
2014). Animals were treated with either saline or PCP once a day for 7 days, according to a 
slightly modified version of the treatment schedule described by Seillier et al. (2010) and A
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shown in ‘Results’. After 7 days of withdrawal, rats were tested in the novel object 
recognition (NOR) test, social interaction test and forced swim test (FST).  
Behavioural tests 
Spontaneous Locomotor Activity 
Rats were placed in a computer-controlled infra-red activity monitor arena. The arena 
consisted of a clear acrylic box, 43×43×32 cm (Ugo Basile, Varese, Italy) placed in a sound-
attenuating room. The cage was fitted with two parallel infrared beams, located 2 and 6 cm 
from the floor and cumulative horizontal and vertical movement counts were recorded for 50 
min. During this period, stereotyped behaviours were scored by two observers blind to the 
treatment groups according to the rating scale described by Sams-Dodd (1998). Horizontal 
locomotor activity and stereotypies were calculated in 10-min blocks. The total scores of the 
whole 50 min test session (i.e. the sum of the scores recorded for each 10 min block) were 
calculated and converted to area under the curve (AUC) values using GraphPad Prism 5.0 
software. 
Novel Object Recognition Test (Classic and Spatial) 
The experimental apparatus used for the object recognition test was an open-field box (43 x 
43 x 32 cm) made of Plexiglas, placed in a dimly illuminated room. Animals performed each 
test individually. The experiment was performed and analyzed as previously described by 
Zamberletti et al. (2012). Briefly, each animal was placed in the arena and allowed to explore 
two identical previously unseen objects for 5 min (familiarization phase). After an inter-trial 
interval of 3 min one of the two familiar objects was replaced by a novel, previously unseen 
object and rats were returned to the arena for the 5-min test phase. During the test phase the 
time spent exploring the familiar object (Ef) and the new object (En) was videotaped and 
recorded separately by two observers blind to the treatment groups and the discrimination 
index was calculated as follows: [(En-Ef)/(En+Ef)] x 100. 
Social Interaction Test 
This test was carried out in a room illuminated with a dim overhead light. On the day of 
testing, each animal was habituated for 10 min in the test arena (60 x 60 x 60 cm), an open-
field box made of Plexiglas. During the test session, each animal was allowed to explore 
freely an unfamiliar congener in the arena for 10 min. The arena was cleaned with 0.1% 
acetic acid and dried after each trial. Social behaviors were defined as sniffing, following, 
grooming, mounting and nosing. Aggressive behaviours were defined as attacking, biting, tail A
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rattling and aggressive grooming. The whole testing phase was videotaped, analyzed by two 
observers blind to the treatment groups; we also recorded the time spent in social behaviors 
and the number of aggressive behaviors. 
Forced Swim Test 
Animals were tested in a modified version of the FST that included only a single session of 
swimming (Realini et al., 2011; Zamberletti et al., 2012), since our objective was to measure 
any changes in a pre-existing behavioral deficit induced by PCP. Briefly, rats were forced to 
swim for 15 min inside a clear 50 cm tall, 20 cm diameter glass cylinder filled to 30 cm with 
25°C water. The session was videotaped for later analysis of the following parameters: 
immobility (time spent by the animal floating in the water making only those movements 
necessary to keep its head above the water), swimming (active swimming movements to the 
centre of the cylinder), and climbing (forceful thrashing movements with forelimbs against 
the walls of the cylinder). The time spent in each of these behaviors was measured by an 
experimenter blind to the treatment groups. 
In Vivo Data Analysis 
Behavioural data were expressed as mean values ± SEM of 6 animals per group and analysed 
by three-way ANOVA with PCP, THCV and WAY100635 as independent variables, or by 
two-way ANOVA with PCP and THCV/CLZ/AM251 as independent variables followed by 
Bonferroni’s post hoc test to examine group differences. The level of statistical significance 
was set at P < 0.05. 
 
Results 
In vitro experiments 
First, we investigated whether THCV shares the ability of CBD to enhance the 
activation of 5-HT1A receptors in rat brainstem membranes. Interestingly, we found that, 
unlike CBD, THCV (100 nM) induced a statistically significant increase (240.9-fold) in the 
potency (EC50), but not in the efficacy (Emax), with which 8-OH-DPAT stimulates 
[
35S]GTPγS binding to these membranes (Figure 2A and Table 2). When tested alone, THCV 
(1 nM to 10 µM) did not affect [
35S]GTPγS binding to the same membranes (Figure 2B). 
Furthermore, we found that in these membranes, THCV potently, but only partially, displaced 
8-[
3
H]-OH-DPAT from specific binding sites (Figure 2C and Table 1).  
Next, we performed experiments with membranes obtained from human 5-HT1A-
transfected CHO cells that, in contrast to brain tissue, do not express other types of receptor. 
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We found that, in these membranes, THCV (100 nM) induced a significant increase in the 
efficacy (Emax), but not in the potency (EC50), with which 8-OH-DPAT activates human 5-
HT1A receptors (Figure 2D and Table 2). When THCV was tested alone in the [
35S]GTPγS 
binding assay, it did not induce any detectable effect at 1 nM to 10 µM (Figure 2E). Also, in 
the same membranes, we found that THCV significantly increased the binding of 8-[
3
H]-OH-
DPAT to specific binding sites (Figure 2F), while the binding of this tritium-labelled 
compound was completely prevented by 8-OH-DPAT (Figure 2F and Table 1).  
Since there is evidence that the 5-HT1A receptor possesses an allosteric binding site 
(Barrondo et al., 2009), we also investigated the ability of the 8-OH-DPAT-potentiating 
concentration of THCV (100 nM) to alter the rate at which 8-[
3
H]-OH-DPAT dissociates 
from specific binding sites in membranes obtained from human 5-HT1A CHO cells (n=4). Our 
experiments showed that this concentration of THCV did not alter this dissociation rate (data 
not shown). 
Effect of THCV administration on PCP-induced behavioural alterations 
Figure 4 shows the effect of THCV administration (2 mg kg
-1
 i.p.) on PCP-induced 
schizophrenia-like symptoms in rats in comparison with the atypical antipsychotic, CLZ (2.5 
mg kg
-1
 i.p.). Two different paradigms of PCP administration were chosen: acute PCP to 
mimic the positive-like signs of schizophrenia (Panel A) and sub-chronic PCP treatment to 
produce the apparent cognitive deficits (Panel B) and negative-like symptoms (Panels C and 
D). 
As expected, acute PCP injection (5 mg kg
-1
 i.p.) induced marked hyperlocomotion 
paralleled by the appearance of stereotyped behaviours during the 50-min test session 
(F1,20=17.56, P=0.0005). THCV treatment per se did not affect locomotor activity in control 
animals but its administration completely normalized PCP-induced hyperlocomotion and 
significantly reduced stereotyped behaviours (THCV: F1,20=4.452, P=0.0477; PCPxTHCV 
interaction: F1,20=5.891, P=0.0248). Similar results were obtained with the atypical 
antipsychotic, CLZ (2.5 mg kg
-1
 i.p.) (two-way ANOVA for PCP: F1,20=14.85, P=0.0010; 
CLZ: F1,20=2.390, P=0.1378; PCPxCLZ interaction: F1,20=5.133, P=0.0347) (Figure  4A). 
Figure 4, Panel B depicts the effect of THCV on the cognitive impairment induced by 
sub-chronic PCP pretreatment in the novel object recognition (NOR) test. Sub-chronic PCP 
significantly impaired recognition memory, as indicated by a significant reduction in the 
discrimination index of about 50 % compared to controls (F1,20=5.266, P=0.0327). It 
induced even greater apparent cognitive impairment in the spatial version of the test, the A
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discrimination index being reduced by about 90 % (F1,20=38.64, p<0.0001). THCV 
administration completely restored recognition memory in PCP-pretreated rats both in the 
classic (THCV: F1,20=14.46, P=0.0010; PCPxTHCV interaction: F1,20=14.46, P=0.0011) 
and in the spatial (THCV: F1,20=11.93, P=0.0025; PCPxTHCV interaction: F1,20=27.30, 
p<0.0001) variants of the NOR test, without having any effect in control animals. The 
recovery induced by THCV was very similar to that observed after CLZ administration 
(Classic NOR: two-way ANOVA for PCP: F1,20=19.27, P=0.0003; CLZ: F1,20=16.47, 
P=0.0006; PCPxCLZ interaction: F1,20=24.09, p<0.0001; Spatial NOR: PCP: F1,20=53.18, 
p<0.0001; CLZ: F1,20=39.67, p<0.0001; PCPxCLZ interaction: F1,20=43.37, p<0.0001). 
Neither the time spent exploring the two identical objects during the familiarization phase nor 
locomotor activity were altered in any of the groups analyzed (data not shown). 
Figure 4, Panel C shows the effect of THCV administration in the social interaction 
test. Sub-chronic PCP pretreatment significantly reduced the amount of time spent in active 
social behaviours in the 10-min test session by about 60 % when compared to vehicle-treated 
rats (F1,20=154.9, p<0.0001). THCV administration restored the normal social behaviour in 
PCP-pretreated rats (THCV: F1,20=84.40, p<0.0001; PCPxTHCV interaction: F1,20=4.641, 
P=0.0436). Similar results were obtained with CLZ (PCP: F1,20=44.19, p<0.0001; CLZ: 
F1,20=9.225, P=0.0065; PCPxCLZ interaction: F1,20=6.465, P=0.0194). Aggressive 
behaviours were not observed in any of the groups under investigation. In the FST, sub-
chronic PCP pretreatment induced a significant increase of about 80 % in the time spent in 
immobility compared to controls (F1,20=11.34, P=0.0031). This was paralleled by a 
simultaneous reduction in swimming activity. THCV administration to PCP-pretreated rats 
completely normalized the time spent in immobility during the test session (THCV: 
F1,20=19.62, P=0.0003; PCPxTHCV interaction: F1,20=11.42, P=0.0030), the effect being 
very similar to that observed following CLZ injection (PCP: F1,20=17.60, P=0.0004; CLZ: 
F1,20=20.89, P=0.0002; PCPxCLZ interaction: F1,20=8.430, P=0.0088). The rescue of this 
parameter was accompanied by the normalization of the amount of time spent in swimming 
activity. 
 
Effect of 5-HT1A receptor blockade on THCV-induced recovery of schizophrenia-like 
symptoms 
Next, we investigated whether the “beneficial” effects exerted by THCV on PCP-
induced schizophrenia-like traits were mediated by 5-HT1A receptors. To do this, a selective 
5-HT1A antagonist, WAY100635 (1 mg kg
-1
 i.p.), was administered prior to THCV according 
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to the treatment protocol shown in Figure 3, and animals were then submitted to behavioural 
testing. WAY100635 administration per se did not affect any of the behavioural responses 
under investigation in control animals. Moreover, treatment with WAY100635 had no effect 
on PCP-induced positive-like (Figure 5A) or negative-like signs (Figures 5C and D). In 
contrast, WAY100635 administration did partially prevent PCP-induced cognitive deficits in 
both variants of the NOR test (Classic NOR: two-way ANOVA for PCP: F1,20=62.82, 
p<0.0001; WAY100635: F1,20=4.617, P=0.0441; PCPxWAY100635 interaction: 
F1,20=11.27, P=0.0031; Spatial NOR: PCP: F1,20=44.90, p<0.0001; WAY100635: 
F1,20=8.892, P=0.0074; PCPxWAY100635 interaction: F1,20=16.22, P=0.0007) (Figure 5B). 
Importantly, WAY100635 did prevent the beneficial effect exerted by THCV on PCP-
induced stereotypies and social withdrawal. Thus, three-way ANOVA indicated both a 
significant PCPxTHCVxWAY100635 interaction (F1,30=5.58, P=0.0053), and a significant 
THCVxWAY100635 interaction (F1,30=7.23, P=0.0095) on stereotypies, the data we 
obtained indicating that WAY100635 pretreatment completely prevented THCV from 
reducing PCP-induced stereotypies (Figure 5A). A similar statistically significant effect was 
observed in the social interaction test (PCPxTHCVxWAY100635 interaction: F1,30=5.046, 
P=0.0129; THCVxWAY100635 interaction: F1,30=8.998, P=0.0071), in which WAY100635 
pretreatment abolished entirely the ability of THCV to prevent PCP-induced social 
withdrawal (Figure 5C). 
In addition, WAY100635 also partially antagonized the recovery induced by THCV on 
PCP-induced cognitive deficits in both the classic (PCPxTHCVxWAY100635 interaction: 
F1,30=11.80, P=0.0002; THCVxWAY100635 interaction: F1,30=11.76, P=0.0027) and the 
spatial (PCPxTHCVxWAY100635 interaction: F1,30=7.690, P=0.0020; THCVxWAY100635 
interaction: F1,30=5.129, P=0.0348) variants of the NOR test (Figure 5B). 
Effect of AM251 administration on PCP-induced behavioural alterations 
Acute administration of AM251 (0.5 mg kg
-1
 i.p.) did not affect PCP-induced 
hyperlocomotion or stereotyped behaviours (Figure 6, Panel A). In contrast, its administration 
completely prevented PCP-induced cognitive impairments in the classic (two-way ANOVA 
for PCP: F1,14=13.69, P=0.0024; AM251: F1,14=6.476, P=0.0234; PCPxAM251 interaction: 
F1,14=9.297, P=0.0087) and spatial (two-way ANOVA for PCP: F1,14=46.72, p<0.0001; 
AM251: F1,14=15.56, P=0.0013; PCPxAM251 interaction: F1,14=22.17, P=0.0003) variants 
of the NOR test (Figure 6, Panel B). Acute AM251 administration also significantly reduced 
PCP-induced negative-like symptoms. Thus, AM251 completely abolished PCP-induced A
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social withdrawal in the social interaction test (two-way ANOVA for PCP: F1,14=4.290, 
P=0.0560; AM251: F1,14=4.696, P=0.0467; PCPxAM251 interaction: F1,14=7.676, 
P=0.0143) (Figure 6, Panel C) and opposed the increased immobility induced by PCP in the 
FST (two-way ANOVA for PCP: F1,14=35.59, p<0.0001; AM251: F1,14=14.93, P=0.0017; 
PCPxAM251 interaction: F1,14=5.560, P=0.0334) by significantly increasing the time spent 
in climbing activity (F1,14=21,91, P=0.0001) (Figure 6, Panel D). 
 
Discussion 
The results from our investigation clearly show that THCV possesses an ability to 
interact with serotoninergic 5-HT1A receptors both in vitro and in vivo. Turning first to our in 
vitro data, these showed that THCV, at 100 nM, significantly increased the potency (EC50) 
but not the efficacy (Emax), with which DPAT activates 5-HT1A receptors in rat brainstem 
membranes, thus behaving as a potential positive allosteric modulator of the 5-HT1A receptor. 
Also, we found that, like 8-OH-DPAT, THCV potently displaced 8-[
3
H]-OH-DPAT from 
specific binding sites in these membranes, although the percentage of the maximum 
displacement induced by 100 nM THCV was significantly lower than that induced by the 
same concentration of 8-OH-DPAT. These results raised the possibility that THCV does not 
bind directly to orthosteric sites on these receptors. Moreover, it remains possible too that 
THCV enhances DPAT-induced 5-HT1A receptor activation through an indirect mechanism 
that involves the targeting by THCV of another kind of receptor. 
To investigate this hypothesis, we performed experiments with human 5-HT1A-
transfected CHO cell membranes that, in contrast to brain membranes, do not express other 
types of receptors. We found that at 100 nM, THCV did significantly increase the binding of 
8-[
3
H]-OH-DPAT to specific binding sites in these CHO cell membranes. However, in 
contrast to the results we obtained with rat brainstem membranes, THCV induced a 
significant increase in the efficacy (Emax), rather than the potency (EC50), with which 8-OH-
DPAT activates the human 5-HT1A receptor. In spite of the different manner in which THCV 
enhanced the effect of 8-OH-DPAT in brain and CHO cell membranes, these results support 
the hypothesis that THCV might behave as a positive allosteric modulator at 5-HT1A 
receptors. However, in the same cells, we found that 100 nM THCV did not alter the rate of 
dissociation of 8-[
3
H]-OH-DPAT from specific binding sites.  
These in vitro results together with evidence already published that activation of 5-
HT1A receptors in vivo can ameliorate at least some signs of schizophrenia (Ohno, 2011; A
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Bantick et al., 2001; Shimizu et al., 2013), prompted us to investigate whether THCV can 
produce any apparent antipsychotic effects in vivo, and if so, whether any of these effects are 
5-HT1A receptor-mediated. This we did in a pharmacological model of schizophrenia in 
which rats are treated acutely or pretreated sub-chronically with PCP. Thus, overall, we found 
first, that on single administration, THCV was as effective as the established atypical 
antipsychotic, CLZ, in reverting both positive- and negative-like signs of schizophrenia, and 
cognitive impairments, and second, that many of the effects of THCV that we observed in 
these in vivo experiments appeared to be mediated, at least in part by the 5-HT1A receptor. In 
rats pretreated with vehicle instead of PCP, neither THCV nor CLZ produced any effect in 
any of the behavioural tests that we used.  
Our in vivo experiments with THCV showed that it prevented hyperlocomotion and 
stereotypies induced by acute PCP administration, and that in the sub-chronic PCP model, it 
restored social behaviours and counteracted the increase in the time spent in immobility in the 
FST. Moreover, THCV administration was able to normalize cognitive performance in PCP-
pretreated rats. Importantly, the ability of THCV to reverse behavioural changes induced by 
acute PCP injections, such as stereotypies and hyperlocomotion, is suggestive of a beneficial 
effect on positive-like signs, whereas its efficacy in normalizing the behavioural alterations 
induced by sub-chronic PCP in the other tests, although not specific to schizophrenia, may 
predict THCV effectiveness for treating negative and cognitive symptoms of this disorder, 
such as memory impairment and deficits in social interaction. 
We also found that pretreatment with the selective 5-HT1A antagonist, WAY100635, 
prevented many of the apparent beneficial effects of THCV on PCP-induced behavioural 
alterations without affecting any of these effects of PCP in the absence of THCV. Thus, the 
ability of THCV to interact in vivo with these receptors might represent one of the molecular 
mechanisms responsible for its antipsychotic-like properties, in line with previous reports 
indicating that increasing the activation of 5-HT1A receptors could be a promising strategy for 
antipsychotic therapy (Bantick et al., 2001; Kleven et al., 2005; Meltzer et al., 2012; 
Newman-Tancredi, 2010). It is noteworthy, however, that although WAY100635 completely 
blocked the reversal by THCV of PCP-evoked stereotypies, it did not reduce the ability of 
THCV to reverse hyperlocomotion induced by acute administration of PCP, indicating that 
this latter effect of THCV was probably not 5-HT1A receptor-mediated. These results suggest 
that 5-HT1A receptors are not mediating the effect of THCV on hyperlocomotion, whereas 
their modulation may be involved in its action on stereotyped behaviours. Our results are in 
line with previous findings obtained with wild-type and 5-HT1A receptor knockout mice that 
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demonstrated that 5-HT1A receptors are implicated in the control of stereotyped movements, 
but not hyperlocomotion, induced by the non-competitive NMDA receptor antagonist, MK-
801 (Scorza et al., 2010). 
Furthermore, our findings that pretreatment with WAY100635 prevented THCV from 
producing any recovery from PCP-induced social withdrawal are in line with evidence 
obtained from other preclinical studies that 5-HT1A agonism can improve PCP-induced social 
behaviour deficits in rodents (Snigdha and Neill, 2008; Depoortere et al., 2007; Bubenikova-
Valesova et al., 2008b), and with the concept that optimized stimulation of 5-HT1A receptors 
is required to maximize treatment benefits with regard to some aspects of social abilities 
(Depoortere et al., 2007; Bruins Slot et al., 2005; Bubenikova-Valesova et al., 2008b). 
Despite the evidence that 5-HT1A receptor agonists can produce apparent anti-depressant 
effects both in traditional and in modified versions of the FST (Lucki et al., 1994; Cryan et 
al., 1997; De Vry, 1995), the ability of THCV to reverse PCP-induced immobility in the FST 
was not dependent upon its action at 5-HT1A receptors, as pre-treatment with WAY10063 did 
not prevent THCV from producing this effect. 
Finally, in the NOR test, WAY100635 by itself partially restored recognition memory 
in PCP-pretreated rats, possibly indicating that 5-HT1A receptors may be involved in the 
impairment of recognition memory triggered by sub-chronic PCP administration in rats. 
Since sub-chronic treatment with PCP has been reported to increase cortical 5-HT1A receptor 
binding (Choi et al., 2009) and 5-HT release (Etou et al., 1998; Martin et al., 1998; Adams 
and Moghaddam, 2001; Amargós-Bosch et al., 2006), it is possible that 5-HT1A antagonism 
could counteract PCP-induced enhancement of serotonergic stimulation, thus resulting in the 
observed improvement of cognitive performance. However, the fact that the reversal by 
THCV of PCP-induced cognitive impairment in the NOR test was not completely prevented 
by WAY100635, suggests that other molecular mechanisms may have contributed to the 
ameliorating effect of THCV in this test.  
One such mechanism may be antagonism of the cannabinoid CB1 receptor by THCV. 
Thus, at the dose used in the present study, THCV has been reported to produce such 
antagonism (Pertwee, 2008) and we hypothesize that this action could contribute to the 
observed recovery of recognition memory induced by THCV since CB1 receptor antagonism 
has been extensively proven to have pro-cognitive effects (De Bruins et al., 2010; Black et al., 
2011; Vaseghi et al., 2012; Guidali et al., 2011; Seillier et al., 2010). In line with previously 
published data, here we demonstrated that the established CB1 receptor antagonist, AM251, 
was effective in reversing the negative-like symptoms and cognitive impairment induced by 
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sub-chronic PCP. Interestingly, unlike THCV, AM251 did not counteract acute PCP-evoked 
hyperlocomotion and stereotypies. This is in line with previous reports that after acute 
administration, CB1 receptor antagonists fail to show any activity in models of positive 
symptoms of schizophrenia (Black et al., 2011; Martin et al., 2003; Thiemann et al., 2008), 
suggesting that antagonism of the CB1 receptor may not reduce such symptoms. In this 
context, its ability to enhance activation of 5-HT1A receptors and block activation of CB1 
receptors simultaneously could make THCV particularly effective as a therapeutic agent for 
the treatment of schizophrenia, a possibility that merits further exploration, for example by 
investigating its efficacy in other animal models of schizophrenia.  
It is well-established that drugs, like rimonabant, that are able to antagonize 
cannabinoid CB1 receptors, may also show depressive-like effects, including suicidality 
(Beyer et al., 2010). The mechanism(s) by which rimonabant shows these side effects are not 
yet known, one possibility being that at high doses rimonabant behaves as an inverse agonist, 
rather than as a ‘neutral’ antagonist at the CB1 receptors (Pertwee et al., 2005). On the 
contrary, THCV, at the dose used in this study (2 mg/kg) lacks of inverse effect, thus 
behaving as a CB1 receptor ‘neutral’ antagonist (Pertwee, 2008). The lack of inverse effect 
might make THCV a drug safer than rimonabant. Moreover, it has been reported that a major 
limitation in the use of neuroleptics is the risk of short- and long-term side effects, such as 
significant weight gain and alterations in glucose metabolism (Shams and Muller, 2014). In 
contrast, THCV has been reported to exert anti-obesity effects in mouse models (Wargent et 
al., 2013), suggesting that, unlike current antipsychotics, its administration would not 
produce unwanted increases in body weight. 
In conclusion, this investigation has shown for the first time that THCV can affect the 
activation of 5-HT1A receptors both in vitro and in vivo. Our in vitro results, obtained from 
experiments performed with both rat brainstem and human 5-HT1A CHO cell membranes, 
strongly support the hypothesis that THCV might modulate the activation of these receptors 
indirectly, rather than by binding directly to their orthosteric sites. Our in vivo experiments 
with rats yielded data showing that, like the established anti-psychotic drug, CLZ, THCV can 
potently antagonize stereotyped behaviour, reduce the amount of time spent immobile in the 
forced swim test, and normalize hyperlocomotor activity, social behaviour and cognitive 
performance in PCP models of schizophrenia-like symptoms. The 5-HT1A receptor antagonist, 
WAY100635, abolished the ability of THCV to modify PCP-induced stereotyped and social 
behaviour, but it had no effect in the FST and only partially reduced the suppressant effect of 
THCV on PCP-induced cognitive deficiency in the NOR test, thus suggesting that these 
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apparent beneficial effects of THCV were not mediated only by 5-HT1A receptors. We 
speculate that one additional action that may underlie these apparent beneficial effects, is the 
antagonism by THCV of the cannabinoid CB1 receptor. 
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Table 1: Mean IC50 and maximal percentage displacement values for the displacement of 8-
[
3
H]-OH-DPAT from specific binding sites in membranes obtained from Sprague Dawley rat 
brainstem or human 5-HT1A CHO cells, with 95% confidence intervals (CI) shown in 
brackets. 
Compound Tissue IC50, nM 
(95% CI) 
Maximal Displacement, % 
(95% CI) 
n 
8-OH-DPAT Rat  
brainstem 
0.8 
(0.4 & 1.4) 
107.6 
(95.4 & 119.8) 
4-9 
Δ9-THCV Rat  
brainstem 
0.002 
(0.0002 & 0.002) 
33.5* 
(27.0 & 40.0) 
4-9 
8-OH-DPAT human 5-HT1A  
CHO cells 
0.9 
(0.5 & 1.7) 
96.5 
(90.1 & 102.9) 
6 
Δ9-THCV human 5-HT1A  
CHO cells 
2060 
(194.6 & 21810) 
-45.4* † 
(-73.5 & -17.4) 
10 
 
*The 95% confidence intervals of this mean value do not overlap with those of the mean 
value in the previous row, indicating it to be significantly lower than the mean value obtained 
from experiments with vehicle-treated membranes (P<0.05). See also Figures 2C and 2F. 
†The 95% confidence intervals of this mean maximal displacement value indicate it to be 
significantly less than zero (P<0.05). See also Figure 2F. 
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Table 2: Effect of 100 nM Δ9-THCV on the mean EC50 and Emax values of 8-OH-DPAT for 
its stimulation of [
35S]GTPγS binding to membranes obtained from Sprague Dawley rat 
brainstem or human 5-HT1A CHO cells, with 95% confidence intervals (CI) shown in 
brackets.  
Pretreatment Tissue EC50, nM 
(95% CI) 
Emax, % 
(95% CI) 
n 
Vehicle 
(DMSO) 
Rat  
brainstem 
1301 
(234 & 7236) 
45.0 
(30.0 & 60.0) 
11 
100 nM THCV Rat  
brainstem 
5.4* 
(0.4 & 67.4) 
34.7 
(27.8 & 41.5) 
11 
Vehicle 
(DMSO) 
human 5-HT1A  
CHO cells 
18.4 
(8.8 & 38.5) 
108.5 
(99.7 & 117.4) 
8 
100 nM THCV human 5-HT1A  
CHO cells 
28.3 
(14.9 & 53.7) 
133.8* 
(124.5 & 143.1) 
8 
 
*The 95% confidence intervals of this mean value do not overlap with those of the mean 
value in the previous row, indicating it to be significantly lower than the mean value obtained 
from experiments with vehicle-treated membranes (P<0.05). See also Figures 2A and 2D. 
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